ELOX earnings: next report 2026-08-10, real EPS beat/miss history, analyst consensus Buy, P/E -2.14. Updated 2026-07-23.
Eloxx Pharmaceuticals (ELOX) Research Hub
Eloxx Pharmaceuticals (ELOX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 15.75 USD (-4.95%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -2.14, market cap 0.09B. This hub links to the full technical, earnings and options research available for ELOX.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 15.75 USD (-4.95%) |
| 52-week range | 10 USD – 23.4 USD |
| Trend regime | Range |
| 14-day RSI | 44.1 (Bearish) |
| Trailing P/E | -2.14 |
| Market cap | 0.09B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-10 |
Available research for ELOX
Covered Call on ELOX: how it works, illustrative setup around the real 15.75 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ELOX: how it works, illustrative setup around the real 15.75 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ELOX: how it works, illustrative setup around the real 15.75 USD price, max profit/loss, breakeven and when to use it. Educational.
ELOX technical analysis: range, last 15.75 USD, RSI 44.1, 52w range 10 USD–23.4 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ELOX in?
Eloxx Pharmaceuticals (ELOX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ELOX in an uptrend or downtrend?
As of 2026-09-11, ELOX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ELOX's trailing P/E ratio?
ELOX's trailing P/E is -2.14, with a market cap of 0.09B. See the earnings research page for full valuation detail.
When does ELOX next report earnings?
ELOX is next scheduled to report earnings on 2026-08-10, with a consensus EPS estimate of -6.4 USD.